FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/06/019734 [Registered on: 18/06/2019] Trial Registered Prospectively
Last Modified On: 24/05/2022
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Unani 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Comparison of unani and allopathic medication for treatment of oral submucous fibrosis  
Scientific Title of Study   Comparison of Unani formulations Zuroor-e-Qula and Jawarish Amla sada with allopathic antioxidants in management of patients with early-intermediate stage oral submucous fibrosis  
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
5/12/154/JMI/IEC/2017 dated 22.12.2017  Protocol Number 
FOD/IRRC/2017/11, Version 3 dated 22.09.2017  Protocol Number 
Z.28015/60/2018-HPC(EMR)-AYUSH dated 14.08.2018  Other 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Arpita Rai 
Designation  Associate Professor 
Affiliation  Faculty of Dentistry, Jamia Millia Islamia 
Address  Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi

South
DELHI
110025
India 
Phone    
Fax    
Email  arai@jmi.ac.in  
 
Details of Contact Person
Scientific Query
 
Name  Arpita Rai 
Designation  Associate Professor 
Affiliation  Faculty of Dentistry, Jamia Millia Islamia 
Address  Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi

South
DELHI
110025
India 
Phone    
Fax    
Email  arai@jmi.ac.in  
 
Details of Contact Person
Public Query
 
Name  Arpita Rai 
Designation  Associate Professor 
Affiliation  Faculty of Dentistry, Jamia Millia Islamia 
Address  Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi

South
DELHI
110025
India 
Phone    
Fax    
Email  arai@jmi.ac.in  
 
Source of Monetary or Material Support  
Extra Mural Research Scheme, Ministry of AYUSH, AYUSH Bhawan, B- Block, GPO Complex, INA New Delhi  
 
Primary Sponsor  
Name  Ministry of AYUSH 
Address  AYUSH Bhawan, B- Block, GPO Complex, INA New Delhi  
Type of Sponsor  Government funding agency 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Arpita Rai  Dental Institute, RIMS  Dept of Oral Medicine and Radiology, Dental Institute, RIMS. Bariyatu, Ranchi - 834009
Ranchi
JHARKHAND 
9871743893

arai@jmi.ac.in 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 3  
Name of Committee  Approval Status 
Institutional Ethical Committee RIMS  Approved 
Institutional Ethics Committee, Jamia Millia Islamia  Approved 
Jamia Millia Islamia  No Objection Certificate 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: L989||Disorder of the skin and subcutaneous tissue, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  SM Fibro  Capsule S M Fibro (contains Alpha Lipoic Acid, Beta-Carotene, Elemental Copper, Elemental Selenium, Lycopene, Vitamin E and Zinc Sulphate as active ingredients) to be taken twice daily for 12 weeks. 
Intervention  Zuroor-e-Qula and Jawarish Amla sada   Jwarish amla sada to be taken with the dose of 6 grams, twice daily for 12 weeks. Drug Zuroor-e-Qula will be given with the instructions to apply on the buccal mucosa, palate, retromolar region, tongue and floor of the mouth twice daily. Total duration of treatment will be 12 weeks. 
 
Inclusion Criteria  
Age From  15.00 Year(s)
Age To  90.00 Year(s)
Gender  Both 
Details  i. Patients with current or previous use of any form of smokeless tobacco and/or areca nut (any duration and frequency)

ii. Patients having early-intermediate stage OSMF designated as Grade I and II by the grading system proposed by Kerr et al (29).

iii. Patients willing to quit the habit of smokeless tobacco and/or areca nut.

iv. Patients willing to accept regular follow-up protocol
 
 
ExclusionCriteria 
Details  i. Patients having advanced stage OSMF designated as Grade III, IV or V by the grading system proposed by Kerr et al.

ii. Any significant medical condition such as scleroderma, anemic stomatitis and diabetes that would interfere with the safety, treatment or compliance with the protocol. Known diabetics or those with altered blood sugar values at the baseline assessment will be excluded from the study.

iii. Patients with known allergy or contra-indication to any of the ingredients of the test drugs.

iv. Patients already undergoing treatment for OSMF.

v. Pregnant and lactating females.

vi. Patients having concomitant pericoronitis or any other dental condition leading to trismus.
 
 
Method of Generating Random Sequence   Random Number Table 
Method of Concealment   On-site computer system 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
a) Inter-incisal mouth opening

b) Tongue protrusion

c) Range of jaw movements

d) Burning sensation/pain 
every 2 weeks for 3 months: 
 
Secondary Outcome  
Outcome  TimePoints 
a) Adverse events or side effects reported after taking the Unani formulations.

b) The impact of OSMF on quality of life of the patients will be assessed.

c) Changes in the oxidative stress.

d) Change in the nutritional status.

e) Habit cessation success rate at 12-week follow-up. 
every 2 weeks for 3 months 
 
Target Sample Size   Total Sample Size="120"
Sample Size from India="120" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/07/2019 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

Oral submucous fibrosis (OSMF) is a chronic, insidious disease that is associated with significant functional morbidity and an increased risk for malignancy. It primarily occurs due to areca nut chewing and is characterized by restricted mouth opening, burning sensation on having hot and spicy food and stiffness and blanching of the oral mucosa. OSMF predominantly affects South Asian and East Asian populations. OSMF is the major health issue affecting 14 million Indian population. The malignant transformation rate of OSMF in India has been reported to as high as 27% over many years.

Treatment of OSMF is a challenge. A wide range of treatment including drug management, surgical therapy, and physiotherapy have been attempted till date, with varying degrees of benefit, but none have been able to cure this disease. Several complementary and alternative medicines have been evaluated in OSMF patients like curcumin, aloe vera, spirullina, allicin  and papain. Anti-oxidants like lycopene obtained from tomato extract and herbal anti-oxidants like oxitard are found to be effective in the management of OSMF.

The classical literature of Unani System of Medicine has a large number of formulations which have been used in various diseases of oral cavity. All the important books such as Kitāb al-HāwÄ« fi’l-Tibb by Muhammad b. Zakariyya RāzÄ« (d. 926),al-Mu‘ālajāt al-Buqrātiyya by AbÅ« Hasan Ahmad b. Muhammad TabarÄ« (d. 985), Kāmil al-Sanā‘a al-Tibbiyyaby ‘AlÄ« b. ‘Abbās MajÅ«sÄ« (d. 994),Ghinā Munāby AbÅ« MansÅ«r Hasan QamrÄ« (d. 999),al-QānÅ«n fi’l-Tibb by Ibn SÄ«nā (d. 1037), al-MÅ«jaz fi’l-Tibbby Ibn NafÄ«s QarshÄ« (d. 1288), Kitāb al-TaysÄ«r fi’l-Madāwa wa-al-TadbÄ«r by Ibn Zuhr (d. 1162), Kitāb al-Mukhtārāt fi’l-Tibbby Ibn Hubal (d. 1213), Sharah al-Asbāb wa-al-‘Alāmāt by NafÄ«s b. ‘Iwaz (d. 1439),  MÄ«zān al-Tibb by Akbar ArzānÄ« (d. 1721), IksÄ«r-i A‘zam by Muhammad A‘zam Khān (d. 1902) have exclusive chapters on the diseases of oral cavity.

Formulations mentioned in different formularies and pharmacopoeias of Unani System of Medicine have never been tried in OSMF patients. The formulations discussed/mentioned under the heading of Qulā‘(Stomatitis) have many ingredients which may be useful in OSMF patients. Secondly, the antioxidants have been found to be beneficial in the cases of OSMF and various studies have reported the benefits of these agents in OSMF. Many single and compound drugs mentioned in the Unani classics have many ingredients which have been shown to possess antioxidant activity and may be useful in OSMF. The individual constituents of the present formulations have also been reported to be safe (18). The current study stems from lacunae in the routine usage of unani formulations for this debilitating oral disorder. Therefore, it was hypothesized that unani formulations could be effective in patients with OSMF due to their anti-inflammatory, potent anti-oxidant and anti-carcinogenic properties. In this study, we propose to evaluate the efficacy and safety of Unani drugs Zuroor-e-Qula and Jawarish Amla sada in the management of early and intermediate stage OSMF.

 

 

 
Close